Last updated: 2026/01/21
Homepage
Home
About Us
Company Overview
Development History
Honors and Qualifications
Corporate Culture
Research Innovation
Technological Platforms
Molecular Discovery Platform
Pilot R & D and Production Platform
Quality Control Platform
Innovation Achievements
FIC! Sungen Biomedical's SGC001 Injection is Approved for Clinical Trials, Achieving Two Approvals Both in China and the United States!
First in the World! Sungen Biomedical Obtains FDA's Clinical Trial Approval of IND SGC001 as An Emergency-use Antibody Drug for AMI
Scientific Frontiers
Immunity
Cell Research
Nat Immunol
News
First Show Vienna! Phase I Clinical Data of the World's First Antibody Drug SGC001 for Acute Myocardial Infarction Unveiled BIO Europe2025
Riding the wave, The world's first acute myocardial infarction antibody SGC001 of Sungen Biomedical was presented at U.S. J.P. Morgan Conference
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
Good News! The Laboratory Animal Management Center at Sungen Biomedical is Granted
Sungen Biomedical Was Awarded the Most Potential Seed Enterprise 2024 by EY Fudan
Good News! The Joint Application Project of Military Medical Research Institute and Sungen Biomedical Won the First Prize
Research Progress of SGC001, The World's First Myocardial Infarction Antibody Drug
Focusing on the Frontier Trends: The First China Pharmaceutical Valley • Future Biological Innovative Drugs Conference
The First China Pharmaceutical Valley • Future Biological Innovative Drugs Conference was successfully held
Techniques for the Preparation of Human Monoclonal Antibodies
Sungen Biomedical Won the First Prize of Beijing Science and Technology Progress Award, Demonstrating Great Scientific Research Capacity
From Acceleration of FIC Antibodies Research by AI to Exploration of New Quality Productivity in the Biomedical Industry
Co-operation to Create a New Chapter in the Research and Development of Biological Innovative Drugs for Cardiovascular Diseases
The Official Opening Ceremony of the 'National Human Brain Health Project' Joint Laboratory was Held in Beijing
Sungen Biomedical and Taizhou People's Hospital Officially Signed a Contract for Integration and Development
An Article in Nature Reveals that the ASGR1-GP73 Axis is a Potential Therapeutic Target for Liver Injury
'X-Gen AI New Drug Discovery and Design Research Center' Published in PLOS Computational Biology
Xinhua Finance: AI Enables 'China's Pharmaceutical Valley' to Accelerate the 'New' Way
Economic Daily: 'China's Pharmaceutical Valley' Relies on AI to Innovate and Develop—Beijing Daxing Technology Enables the Biomedical Industry
Beijing Daily: To Help Medical Treatment by the Wisdom of Science and Technology
Professor Jie Du was Selected as One of the 'Top 2% of Global Scientists with Lifetime Scientific Impact 2024'
Sungen Biomedical Won 2024 Top 10 Innovative Pharmaceutical Enterprises Selected by China Times
World Heart Attack Day | BRTV, Is It True That a Single Shot Can Cure the Heart Attack?
Make More Efforts and Focus on Innovation! The First China Pharmaceutical Valley • Future Biological Innovative Drugs Conference
Sungen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
The Classic Formulation of Antibody Drugs
Three Major Forms of Antibody Therapy
Differences Between Biological Macromolecule Drugs and Chemical Small Molecule Drugs
Biopharmaceutical CMC Process
Another milestone! Sungen Biomedical presented anti-tumor bispecific antibody SGT003 at the JP Morgan Healthcare Annual Conference.
Components of Antibody Drug Conjugates
The Role and Development Trends of Antibody Drugs
The Mechanism of Action of Bispecific Antibody Therapy
What Are the Types of Bispecific Antibodies?
How AI Accelerates Antibody Discovery
How AI is Transforming the Pharmaceutical Industry?
Sungen Biomedical is listed on the 3rd KPMG China's Top 50 Bioinnovation Companies
Sungen Biomedical obtained the honorary title of Model Collective of Beijing Municipality
Opportunities and Challenges of AI-Powered Drug Development
What Are Antibody Drugs?
What is the Difference Between Macromolecules and Small Molecules?
How AI Revolutionizes Drug Development
What are Bispecific Antibodies and Their Therapeutic Potential?
Monoclonal vs. Bispecific Antibodies
Quality Assurance and Quality Control in Pharmaceutical Company
AI in Antibody Discovery
Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs is established to help China break through the global of innovative drugs
A major breakthrough! A phase Ib clinical study of SGC001, a “global pioneer” antibody drug for acute myocardial infarction by Sungen, has achieved positive results
Sungen to Showcase China's Innovative Power at JPM 2026
2026China FIC Innovation & Collaboration Sumit
CHINADAILY | US-China biotech summit builds bridges for innovative drug partners
2026 JPM Focus Series | Focusing on CTLA4 dual-target innovative platform, Sungen Released Preclinical Results of Anti-Tumor Therapeutic Bspecific Antibody SGT003 in cancer treatment for the first time
2026 China FIC Innovation and Collaboration Summit Held in San Francisco, Chinese Pharmaceutical Companies Showcase Innovative Achievements
Career
Learning and Development
Benefits & Compensation
Contact Us
Last updated: 2026/01/21
Homepage